Browse diseases

…cisions about their health and social care. In order to achieve Hepatitis B elimination targets, co-designed models of Hepatitis B care mus…

…sed population-weighted national effectiveness.Results Reported hepatitis B cases amounted to 4 452 376 in China among the study population…

…-negative and one (7.1%) HBeAg-positive subjects presented with hepatocellular carcinoma.Conclusion These data confirm the high prevalence of HIV/HBV co…

…ent monoclonal antibody against B lymphocytes; life-threatening Hepatitis B reactivation is well described following use and screening for …

…Hepatitis B remains a global health concern, with an estimated 1.2 million …

…A) therapy be initiated in patients with inactive CHB with high hepatitis B surface antigen (HBsAg) levels?…

…Background In the hepatitis B e antigen positive (HBeAg+) chronic infection disease phase, ap…

…also shared their data from 4386 patients with inactive chronic hepatitis B (CHB), which showed similarities with our findings.1…

… were included. At the start of peg-IFN therapy (SOT), 44% were hepatitis B envelope antigen (HBeAg) positive, mean HBsAg level was 3.03 lo…

…illion people chronically infected, and is the leading cause of hepatocellular carcinoma worldwide. 1 Tenofovir (TDF) is an effective treatment for HBV …

…ue to the long-term complications including liver cirrhosis and hepatocellular carcinoma. Accordingly, it is imperative to evaluate the temporal trends …

…RPV LA) is an effective treatment option for people living with HIV. Unlike regimens containing tenofovir with lamivudine (3TC) or …